Monitor for next-step clinical development plans for S4V2 and for IXCHIQ real-world effectiveness data from the Brazilian campaign. No revenue or earnings guidance was provided.
Drugs in focus
VALN drug pipeline →IXCHIQ
▼ Bearish Named in this 6-K- Impact
- Phase
- Approved
- Time to market
- Already approved and marketed in the EU, Canada, Brazil and select other markets (approved November 2023 in the US, but US and UK authorizations have been withdrawn).
- Next catalyst
- None dated
What to watchIXCHIQ's commercial future hinges on whether Valneva can rebuild regulatory trust after the US and UK withdrawals. The positive five-year durability data (94% seroresponse) supports the vaccine's efficacy case, but safety concerns remain the dominant overhang. Valneva reports nine-month 2026 results on November 24, which will provide the clearest read on IXCHIQ's ongoing revenue contribution from EU, Canada and Brazil markets.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $5.66entry
- T+1 · 16h ago −0.18%α +1.73% · $5.65
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Valneva reported positive five-year antibody persistence data for its chikungunya vaccine IXCHIQ, showing 94% seroresponse in 221 evaluable participants, and positive Phase 2 results for its Shigella vaccine candidate S4V2, which met its primary endpoint in a CHIM trial. These are clinical development updates, not financial results; no revenue or EPS figures were reported.
Key Facts
- 94% of 221 evaluable participants maintained seroresponse five years after a single dose of IXCHIQ
- Antibody persistence in adults 65+ was comparable to adults 18-64
- Phase 2 infant trial for S4V2 showed statistically significant immune responses for all four Shigella serotypes
- Phase 2 CHIM trial for S4V2 met its primary endpoint with statistically significant reduction in shigellosis incidence
- FDA granted Fast Track designation to S4V2 in 2024
- Brazilian Pilot Vaccination Strategy vaccinated nearly 80,000 adults with IXCHIQ between Feb-Oct 2026
Financial Impact
No financial figures reported; clinical data updates only
Risk Factors
- Clinical trial results may not predict regulatory approval or commercial success
- S4V2 requires further dose optimization and clinical evaluation before pivotal trials
- IXCHIQ commercial adoption depends on outbreak demand and public health campaigns
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001628280-26-073616 |
| Document: a2026_11x09xs4v2xinfant-ch.htm | 0001628280-26-073616 |
| Document: a6-kcoverpagetemplate.htm | 0001628280-26-073616 |
| Document: 0001628280-26-073616-index-headers.html | 0001628280-26-073616 |
| Document: 0001628280-26-073616-index.html | 0001628280-26-073616 |
| Document: 0001628280-26-073616.txt | 0001628280-26-073616 |
| Earnings Context (Synthetic; results releases only) | 0001628280-26-073616 |
Track record
9 reports on VALN
Filters
- Nov 13, 20263d ago 6-K Neutral 4/10 Viewing Entry $5.66 Now $5.65 −0.18% settles Dec 14
- Nov 6, 202610d ago 6-K Neutral 2/10 Entry $5.51 Now $5.65 +2.54% settles Dec 7
- Oct 15, 20264w ago 6-K Neutral 2/10 Entry $5.91 to $5.76 Now $5.65 −4.40% ▼ −2.54% −0.64% vs SPY
- Oct 8, 20265w ago 6-K Neutral 3/10 Entry $5.69 to $5.64 Now $5.65 −0.70% ▼ −0.88% +4.41% vs SPY
- Jun 17, 202621w ago EFFECT Neutral 3/10 Entry $5.35 to $5.08 Now $5.65 +5.61% ▼ −5.05% −6.36% vs SPY
- Jun 5, 202623w ago 6-K Neutral 2/10 Entry $5.48 to $5.40 Now $5.65 +3.10% ▼ −1.46% −3.32% vs SPY
- Jun 1, 202624w ago 6-K Neutral 2/10 Entry $5.95 to $5.23 Now $5.65 −5.04% ▼ −12.10% −10.80% vs SPY
- May 5, 202627w ago 6-K Neutral 2/10 Entry $5.29 to $5.63 Now $5.65 +6.81% ▲ +6.43% +1.47% vs SPY
- Mar 26, 202633w ago 6-K Neutral 3/10 Entry $6.32 to $5.50 Now $5.65 −10.60% ▼ −12.97% −23.64% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers